Business Description
TG Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US88322Q1085
Share Class Description:
TGTX: Ordinary SharesDescription
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.34 | |||||
| Equity-to-Asset | 0.33 | |||||
| Debt-to-Equity | 1.32 | |||||
| Debt-to-EBITDA | 42.64 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | 5.99 | |||||
| Beneish M-Score | -0.97 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 1063 | |||||
| 3-Year FCF Growth Rate | 51.5 | |||||
| 3-Year Book Growth Rate | -34 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 194.49 | |||||
| Future 3-5Y Total Revenue Growth Rate | 48.61 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 72.29 | |||||
| 9-Day RSI | 69.52 | |||||
| 14-Day RSI | 67.95 | |||||
| 6-1 Month Momentum % | 39.8 | |||||
| 12-1 Month Momentum % | 84.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.59 | |||||
| Quick Ratio | 3.91 | |||||
| Cash Ratio | 2.73 | |||||
| Days Inventory | 747.95 | |||||
| Days Sales Outstanding | 97.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.5 | |||||
| Shareholder Yield % | -0.82 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 88.32 | |||||
| Operating Margin % | -0.19 | |||||
| Net Margin % | -5.43 | |||||
| FCF Margin % | -10.61 | |||||
| ROE % | -8.4 | |||||
| ROA % | -3.55 | |||||
| ROIC % | -0.59 | |||||
| ROC (Joel Greenblatt) % | 8.02 | |||||
| ROCE % | 1.79 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 36.1 | |||||
| PS Ratio | 20.6 | |||||
| PB Ratio | 28.36 | |||||
| Price-to-Tangible-Book | 28.36 | |||||
| EV-to-EBIT | 950.04 | |||||
| EV-to-EBITDA | 900.71 | |||||
| EV-to-Revenue | 20.25 | |||||
| EV-to-Forward-Revenue | 9.91 | |||||
| EV-to-FCF | -190.88 | |||||
| Price-to-Net-Current-Asset-Value | 30.17 | |||||
| Earnings Yield (Greenblatt) % | 0.11 | |||||
| FCF Yield % | -0.52 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TGTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TG Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 264.79 | ||
| EPS (TTM) ($) | -0.11 | ||
| Beta | 2.77 | ||
| Volatility % | 73.88 | ||
| 14-Day RSI | 67.95 | ||
| 14-Day ATR ($) | 2.135005 | ||
| 20-Day SMA ($) | 30.37825 | ||
| 12-1 Month Momentum % | 84.23 | ||
| 52-Week Range ($) | 12.37 - 36.84 | ||
| Shares Outstanding (Mil) | 155.67 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TG Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TG Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
TG Therapeutics Inc Frequently Asked Questions
What is TG Therapeutics Inc(TGTX)'s stock price today?
The current price of TGTX is $35.00. The 52 week high of TGTX is $36.84 and 52 week low is $12.37.
When is next earnings date of TG Therapeutics Inc(TGTX)?
The next earnings date of TG Therapeutics Inc(TGTX) is 2025-02-28 Est..
Does TG Therapeutics Inc(TGTX) pay dividends? If so, how much?
TG Therapeutics Inc(TGTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers